Animal models for opioid addiction drug discovery

Bibliography

• Way EL. History of opiate use in the Orient and the United States. Ann N Y Acad Sci 1982;398:12-23
   PubMed Web of Science ®Google Scholar
• Kramer JC. Opium rampant: medical use, misuse and abuse in Britain and the West in the 17th and 18th centuries. Addiction 1979;74(4):377-89
   Web of Science ®Google Scholar
• Weber MM, Emrich HM. Current and historical concepts of opiate treatment in psychiatric disorders. Int Clin Psychopharmacol 1988;3(3):255-66
   PubMed Web of Science ®Google Scholar
• Jonnes JJ. The rise of the modern addict. Am J Public Health (N Y) 1995;85(8 Pt 1):1157-62
   Google Scholar
• Dejean C, Boraud T, Le Moine C. Opiate dependence induces network state shifts in the limbic system. Neurobiol Dis 2013;59:220-9
   PubMed Web of Science ®Google Scholar
• Ahmed SH, Koob GF. Transition from moderate to excessive drug intake: change in hedonic set point. Science 1998;282(5387):298-300
   PubMed Web of Science ®Google Scholar
• Koob GF, Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 1997;278(5335):52-8
   PubMed Web of Science ®Google Scholar
• Warner M, Chen LH, Makuc DM, et al. Drug poisoning deaths in the United States, 1980-2008. NCHS Data Brief 2011;(81):1-8
   PubMedGoogle Scholar
• Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease. Lancet 2012;379(9810):55-70
   PubMed Web of Science ®Google Scholar
• Hser Y-I, Saxon AJ, Huang D, et al. Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 2014;109(1):79-87
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Bucello C, Mathers B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011;106(1):32-51
   PubMed Web of Science ®Google Scholar
• Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the future national results on adolescent drug use: overview of key findings, 2010. Institute for Social Research. Institute for Social Research. University of Michigan, Ann Arbor, MI; 2011. Available from: http://www.isr.umich.edu
   Google Scholar
• Compton WM, Volkow ND. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend 2006;83:S4-7
   PubMed Web of Science ®Google Scholar
• Gilson AM, Ryan KM, Joranson DE, Dahl JL. A reassessment of trends in the medical use and abuse of opioid analgesics and implications for diversion control: 1997-2002. J Pain Symptom Manage 2004;28(2):176-88
   PubMed Web of Science ®Google Scholar
• Gureje OO, Korff Von MM, Simon GEG, Gater RR. Persistent pain and well-being: a World Health Organization Study in Primary Care. JAMA 1998;280(2):147-51
   PubMed Web of Science ®Google Scholar
• Zacny J, Bigelow G, Compton P, Foley K. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend 2003;69(3):215-32
   PubMed Web of Science ®Google Scholar
• McCabe SE, Schulenberg JE, O’Malley PM, et al. Non-medical use of prescription opioids during the transition to adulthood: a multi-cohort national longitudinal study. Addiction 2014;109(1):102-10
   PubMed Web of Science ®Google Scholar
• Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 38 cases. Pain 1986;25(2):171-86
   PubMed Web of Science ®Google Scholar
• Boudreau D, Korff Von M, Rutter CM, et al. Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf 2009;18(12):1166-75
   PubMed Web of Science ®Google Scholar
• Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain 2004;109(3):514-19
   PubMed Web of Science ®Google Scholar
• Sullivan MD, Edlund MJ, Fan M-Y, et al. Trends in use of opioids for non-cancer pain conditions 2000–2005 in Commercial and Medicaid insurance plans: the TROUP study. Pain 2008;138(2):440-9
   PubMed Web of Science ®Google Scholar
• Chabal CC, Erjavec MKM, Jacobson LL, et al. Prescription opiate abuse in chronic pain patients: clinical criteria, incidence, and predictors. Clin J Pain 1997;13(2):150-5
   PubMed Web of Science ®Google Scholar
• Chelminski PR, Ives TJ, Felix KM, et al. A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity. BMC Health Serv Res 2005;5(1):3
   PubMedGoogle Scholar
• Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend 2006;81(2):103-7
   PubMed Web of Science ®Google Scholar
• Cowan DT, Wilson-Barnett J, Griffiths P, Allan LG. A survey of chronic noncancer pain patients prescribed opioid analgesics. Pain Med 2003;4(4):340-51
   PubMed Web of Science ®Google Scholar
• Jonasson U, Jonasson B, Wickström L, et al. Analgesic use disorders among orthopedic and chronic pain patients at a rehabilitation clinic. Subst Use Misuse 1998;33(6):1375-85
   PubMed Web of Science ®Google Scholar
• Michna E, Ross EL, Hynes WL, et al. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage 2004;28(3):250-8
   PubMed Web of Science ®Google Scholar
• Schieffer BM, Pham Q, Labus J, et al. Pain Medication Beliefs and Medication Misuse in Chronic Pain. J Pain 2005;6(9):620-9
   PubMed Web of Science ®Google Scholar
• Warner M, Chen LH, Makuc DM. Increase in fatal poisonings involving opioid analgesics in the United States, 1999-2006. NCHS Data Brief 2009;22):1-8
   PubMedGoogle Scholar
• Blanco C, Alderson D, Ogburn E, et al. Changes in the prevalence of non-medical prescription drug use and drug use disorders in the United States: 1991-1992 and 2001-2002. Drug Alcohol Depend 2007;90(2-3):252-60
   PubMed Web of Science ®Google Scholar
• McCabe SE, Cranford JA, Boyd CJ. The relationship between past-year drinking behaviors and nonmedical use of prescription drugs: Prevalence of co-occurrence in a national sample. Drug Alcohol Depend 2006;84(3):281-8
   PubMed Web of Science ®Google Scholar
• McCabe SE, West BT, Morales M, et al. Does early onset of non-medical use of prescription drugs predict subsequent prescription drug abuse and dependence? Results from a national study. Addiction 2007;102(12):1920-30
   PubMed Web of Science ®Google Scholar
• SAMHSA. The DAWN Report: Trends in Emergency Department Visits Involving Nonmedical Use of Narcotic Pain Relievers. [Internet]. Rockville, MD; 2010. p. 1-4. Available from: http://oas.samhsa.gov/2k10/dawn016/opioided.htm
   Google Scholar
• Kaplan GB, Hammer RP. Brain circuitry and signaling in psychiatry: basic science and clinical. American Psychiatric Publishing, Inc Washington, DC London, England. Google Books 2008
   Google Scholar
• Baik J-H. Dopamine signaling in reward-related behaviors. Front Neural Circuits 2013;7:152
   PubMed Web of Science ®Google Scholar
• Mogenson GJ, Jones DL, Yim CY. From motivation to action: functional interface between the limbic system and the motor system. Prog Neurobiol 1980;14(2):69-97
   PubMed Web of Science ®Google Scholar
• Woollett K, Maguire EA. Acquiring “the Knowledge” of London’s layout drives structural brain changes. Curr Biol 2011;21(24):2109-14
   PubMed Web of Science ®Google Scholar
• Bodnar RJ. Endogenous opiates and behavior: 2012. Peptides 2013;50:55-95
   PubMed Web of Science ®Google Scholar
• Goodman A. Neurobiology of addiction. Biochem Pharmacol 2008;75(1):266-322
   PubMed Web of Science ®Google Scholar
• Cepeda C, Levine MS. Dopamine and N-methyl-D- aspartate receptor interactions in the neostriatum. Dev Neurosci 2012;20(1):1-18
   Google Scholar
• Navratilova E, Xie JY, King T, Porreca F. Evaluation of reward from pain relief. Ann N Y Acad Sci 2013;1282:1-11
   PubMed Web of Science ®Google Scholar
• Mazei-Robison MS, Appasani R, Edwards S, et al. Self-administration of ethanol, cocaine, or nicotine does not decrease the soma size of ventral tegmental area dopamine neurons. PLoS One 2014;9(4):e95962-
   PubMed Web of Science ®Google Scholar
• Ikemoto S, Bonci A. Neurocircuitry of drug reward. Neuropharmacology 2014;76(Pt B):329-41
   PubMedGoogle Scholar
• Gallistel CRC, Karras DD. Pimozide and amphetamine have opposing effects on the reward summation function. Pharmacol Biochem Behav 1984;20(1):73-7
   PubMed Web of Science ®Google Scholar
• Gerfen CR. D1 dopamine receptor supersensitivity in the dopamine-depleted striatum animal model of Parkinson’s disease. Neuroscientist 2003;9(6):455-62
   PubMed Web of Science ®Google Scholar
• Nakazato T, Akiyama A. Behavioral activity and stereotypy in rats induced by L-DOPA metabolites: a possible role in the adverse effects of chronic L-DOPA treatment of Parkinson’s disease. Brain Res 2002;930(1-2):134-42
   PubMed Web of Science ®Google Scholar
• Trugman JMJ. D1/D2 actions of dopaminergic drugs studied with [14C]-2-deoxyglucose autoradiography. Prog Neuropsychopharmacol Biol Psychiatry 1995;19(5):795-810
   PubMed Web of Science ®Google Scholar
• Ueda HH, Sato KK, Okumura FF, et al. Supersensitization of neurochemical responses by L-DOPA and dopamine receptor agonists in the striatum of experimental Parkinson’s disease model rats. Biomed Pharmacother 1995;49(4):169-77
   PubMed Web of Science ®Google Scholar
• Zhen XX, Torres CC, Cai GG, Friedman EE. Inhibition of protein tyrosine/mitogen-activated protein kinase phosphatase activity is associated with D2 dopamine receptor supersensitivity in a rat model of Parkinson’s disease. Mol Pharmacol 2002;62(6):1356-63
   PubMed Web of Science ®Google Scholar
• Koch T, Höllt V. Role of receptor internalization in opioid tolerance and dependence. Pharmacol Ther 2008;117(2):199-206
   PubMed Web of Science ®Google Scholar
• Meng J, Malanga CJ, Kong JQ, et al. Hyperpolarizing effects of morphine, clonidine and 2-chloroadenosine in myenteric neurons associated with tolerance to morphine. J Pharmacol Exp Ther 1997;281(1):41-7
   PubMed Web of Science ®Google Scholar
• Christie MJ. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 2008;154(2):384-96
   PubMed Web of Science ®Google Scholar
• Creed MC, Lüscher C. Drug-evoked synaptic plasticity: beyond metaplasticity. Curr Opin Neurobiol 2013;23(4):553-8
   PubMed Web of Science ®Google Scholar
• Kodangattil JN, Dacher M, Authement ME, Nugent FS. Spike timing-dependent plasticity at GABAergic synapses in the ventral tegmental area. J Physiol 2013;591(Pt 19):4699-710
   PubMed Web of Science ®Google Scholar
• Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. Am J Psychiatry 2005;162(8):1403-13
   PubMed Web of Science ®Google Scholar
• Graybiel AM. Habits, rituals, and the evaluative brain. Annu Rev Neurosci 2008;31:359-87
   PubMed Web of Science ®Google Scholar
• Mao L, Guo M, Jin D, et al. Group III metabotropic glutamate receptors and drug addiction. Front Med 2013;7(4):445-51
   PubMed Web of Science ®Google Scholar
• De Vries TJ, Shippenberg TS. Neural systems underlying opiate addiction. J Neurosci 2002;22(9):3321-5
   PubMed Web of Science ®Google Scholar
• Mao J, Sung B, Ji R-R, Lim G. Chronic morphine induces downregulation of spinal glutamate transporters: implications in morphine tolerance and abnormal pain sensitivity. J Neurosci 2002;22(18):8312-23
   PubMed Web of Science ®Google Scholar
• Lee MM, Silverman MS, Hansen H, et al. A comprehensive review of opioid-induced hyperalgesia. Pain 2011;14(2):145-61
   Web of Science ®Google Scholar
• Branch CAC, Knuepfer MMM. Causes of differential cardiovascular sensitivity to cocaine. I: studies in conscious rats. J Pharmacol Exp Ther 1994;269(2):674-83
   PubMed Web of Science ®Google Scholar
• Kalsner SS. Cocaine sensitization of coronary artery contractions: mechanism of drug-induced spasm. J Pharmacol Exp Ther 1993;264(3):1132-40
   PubMed Web of Science ®Google Scholar
• Riezzo II, Fiore CC, De Carlo DD, et al. Side effects of cocaine abuse: multiorgan toxicity and pathological consequences. Curr Med Chem 2012;19(33):5624-46
   PubMed Web of Science ®Google Scholar
• Dackis CA, Gold MS. Addictiveness of central stimulants. Adv Alcohol Subst Abuse 1990;9(1-2):9-26
   PubMedGoogle Scholar
• Vanderah TW, Gardell LR, Burgess SE, et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J Neurosci 2000;20(18):7074-9
   PubMed Web of Science ®Google Scholar
• King T, Ossipov MH, Vanderah TW, et al. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance? Neurosignals 2005;14(4):194-205
   PubMed Web of Science ®Google Scholar
• Hser YI, Anglin D, Powers K. A 24-year follow-up of California narcotics addicts. Arch Gen Psychiatry 1993;50(7):577-84
   PubMed Web of Science ®Google Scholar
• Wilcox HC, Conner KR, Caine ED. Association of alcohol and drug use disorders and completed suicide: an empirical review of cohort studies. Drug Alcohol Depend 2004;76(Suppl):S11-19
   PubMed Web of Science ®Google Scholar
• UNODC. World Drug Report 2012 [Internet]. 2012. p. 1-112. Available from: http://www.unodc.org/documents/data-and-analysis/WDR2012/WDR_2012_web_small.pdf [Cited 3 June 2014]
   Google Scholar
• Krupitsky E, Nunes EV, Ling W, et al. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction 2013;108(9):1628-37
   PubMed Web of Science ®Google Scholar
• Fischer B, Nakamura N, Rush B, et al. Changes in and characteristics of admissions to treatment related to problematic prescription opioid use in Ontario, 2004-2009. Drug Alcohol Depend 2010;109(1-3):257-60
   PubMed Web of Science ®Google Scholar
• Brands B, Blake J, Sproule B, et al. Prescription opioid abuse in patients presenting for methadone maintenance treatment. Drug Alcohol Depend 2004;73(2):199-207
   PubMed Web of Science ®Google Scholar
• Silversides A. Ontario takes aim at painkiller abuse. CMAJ 2009;181(8):E141-2
   PubMed Web of Science ®Google Scholar
• Kahan M, Srivastava A, Wilson L, et al. Misuse of and dependence on opioids: study of chronic pain patients. Can Fam Physician 2006;52(9):1081-7
   PubMedGoogle Scholar
• Wallisch M, Nelson CS, Mulvaney JM, et al. Effects of chronic opioid exposure on guinea pig mu opioid receptor in Chinese hamster ovary cells: comparison with human and rat receptor. Biochem Pharmacol 2007;73(11):1818-28
   PubMed Web of Science ®Google Scholar
• Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 1998;93(4):515-32
   PubMed Web of Science ®Google Scholar
• Cornish R, Macleod J, Strang J, et al. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010;341:c5475
   PubMed Web of Science ®Google Scholar
• Degenhardt L, Randall D, Hall W, et al. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend 2009;105(1):9-15
   PubMed Web of Science ®Google Scholar
• Gibson A, Degenhardt L, Mattick RP, et al. Exposure to opioid maintenance treatment reduces long-term mortality. Addiction 2008;103(3):462-8
   PubMed Web of Science ®Google Scholar
• Kimber J, Copeland L, Hickman M, et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ 2010;341:c3172-
   PubMed Web of Science ®Google Scholar
• Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 2000;283(10):1303-10
   PubMed Web of Science ®Google Scholar
• Brewer DD, Catalano RF, Haggerty K, et al. A meta-analysis of predictors of continued drug use during and after treatment for opiate addiction. Addiction 1998;93(1):73-92
   PubMed Web of Science ®Google Scholar
• Magura S, Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med 2001;68(1):62-74
   PubMed Web of Science ®Google Scholar
• Martin WR, Jasinski DR, Mansky PA. Naltrexone, an antagonist for the treatment of heroin dependence. Effects in man. Arch Gen Psychiatry 1973;28(6):784-91
   PubMed Web of Science ®Google Scholar
• Mello NK, Mendelson JH, Kuehnle JC, Sellers MS. Operant analysis of human heroin self-administration and the effects of naltrexone. J Pharmacol Exp Ther 1981;216(1):45-54
   PubMed Web of Science ®Google Scholar
• Walsh SL, Sullivan JT, Preston KL, et al. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. J Pharmacol Exp Ther 1996;279(2):524-38
   PubMed Web of Science ®Google Scholar
• Sullivan MA, Garawi F, Bisaga A, et al. Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend 2007;91(2):289-92
   PubMed Web of Science ®Google Scholar
• Comer SD, Sullivan MA, Hulse GK. Sustained-release naltrexone: novel treatment for opioid dependence. Expert Opin Investig Drugs 2007;16(8):1285-94
   PubMed Web of Science ®Google Scholar
• Adi Y, Juarez-Garcia A, Wang D, et al. Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation. Health Technol Assess 2007;11(6):iii-85
   PubMed Web of Science ®Google Scholar
• Modesto-Lowe V, Van Kirk J. Clinical uses of naltrexone: a review of the evidence. Exp Clin Psychopharmacol 2002;10(3):213-27
   PubMed Web of Science ®Google Scholar
• Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011;4):CD001333
   Web of Science ®Google Scholar
• Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2008;2):CD002207
   PubMed Web of Science ®Google Scholar
• Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009;3):CD002209
   PubMed Web of Science ®Google Scholar
• Krupitsky EM, Zvartau EE, Masalov DV, et al. Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat 2004;26(4):285-94
   PubMed Web of Science ®Google Scholar
• Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003;349(10):949-58
   PubMed Web of Science ®Google Scholar
• Newman R, Whitehill W. Double-blind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet 1979;314(8141):485-8
   Google Scholar
• Everly JJ, DeFulio A, Koffarnus MN, et al. Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial. Addiction 2011;106(7):1309-18
   PubMed Web of Science ®Google Scholar
• Colantuoni C, Rada P, McCarthy J, et al. Evidence that intermittent, excessive sugar intake causes endogenous opioid dependence. Obes Res 2002;10(6):478-88
   PubMedGoogle Scholar
• File SE, Andrews N, al-Farhan M. Anxiogenic responses of rats on withdrawal from chronic ethanol treatment: effects of tianeptine. Alcohol Alcohol 1993;28(3):281-6
   PubMed Web of Science ®Google Scholar
• Mutschler NHN, Miczek KAK. Withdrawal from a self-administered or non-contingent cocaine binge: differences in ultrasonic distress vocalizations in rats. Psychopharmacology (Berl) 1998;136(4):402-8
   PubMed Web of Science ®Google Scholar
• Kelley AE, Bakshi VP, Fleming S, Holahan MR. A pharmacological analysis of the substrates underlying conditioned feeding induced by repeated opioid stimulation of the nucleus accumbens. Neuropsychopharmacology 2000;23(4):455-67
   PubMed Web of Science ®Google Scholar
• Hoebel BG, Monaco AP, Hernandez L, et al. Self-injection of amphetamine directly into the brain. Psychopharmacology (Berl) 1983;81(2):158-63
   PubMed Web of Science ®Google Scholar
• McBride WJ, Murphy JM, Ikemoto S. Localization of brain reinforcement mechanisms: intracranial self-administration and intracranial place-conditioning studies. Behav Brain Res 1999;101(2):129-52
   PubMed Web of Science ®Google Scholar
• Olds ME. Reinforcing effects of morphine in the nucleus accumbens. Brain Res 1982;237(2):429-40
   PubMed Web of Science ®Google Scholar
• Wise RA. Opiate reward: sites and substrates. Neurosci Biobehav Rev 1989;13(2-3):129-33
   PubMed Web of Science ®Google Scholar
• Avena NM. Examining the addictive-like properties of binge eating using an animal model of sugar dependence. Exp Clin Psychopharmacol 2007;15(5):481-91
   PubMed Web of Science ®Google Scholar
• Pothos E, Rada P, Mark GP, Hoebel BG. Dopamine microdialysis in the nucleus accumbens during acute and chronic morphine, naloxone-precipitated withdrawal and clonidine treatment. Brain Res 1991;566(1-2):348-50
   PubMed Web of Science ®Google Scholar
• Rada P, Mark GP, Pothos E, Hoebel BG. Systemic morphine simultaneously decreases extracellular acetylcholine and increases dopamine in the nucleus accumbens of freely moving rats. Neuropharmacology 1991;30(10):1133-6
   PubMed Web of Science ®Google Scholar
• Rada P, Pothos E, Mark GP, Hoebel BG. Microdialysis evidence that acetylcholine in the nucleus accumhens is involved in morphine withdrawal and its treatment with clonidine. Brain Res 1991;561(2):354-6
   PubMed Web of Science ®Google Scholar
• Fiserová M, Consolo S, Krsiak M. Chronic morphine induces long-lasting changes in acetylcholine release in rat nucleus accumbens core and shell: an in vivo microdialysis study. Psychopharmacology (Berl) 1999;142(1):85-94
   PubMed Web of Science ®Google Scholar
• Rada PV, Mark GP, Taylor KM, Hoebel BG. Morphine and naloxone, i.p. or locally, affect extracellular acetylcholine in the accumbens and prefrontal cortex. Pharmacol Biochem Behav 1996;53(4):809-16
   PubMed Web of Science ®Google Scholar
• Chu LF, Liang D-Y, Li X, et al. From mouse to man: the 5-HT3 receptor modulates physical dependence on opioid narcotics. Pharmacogenet Genomics 2009;19(3):193-205
   PubMed Web of Science ®Google Scholar
• Bickel WK, Stitzer ML, Wazlavek BE, Liebson IA. Naloxone-precipitated withdrawal in humans after acute morphine administration. NIDA Res Monogr 1986;67:349-54
   PubMedGoogle Scholar
• Self DW, Nestler EJ. Relapse to drug-seeking: neural and molecular mechanisms. Drug Alcohol Depend 1998;51(1-2):49-60
   PubMed Web of Science ®Google Scholar
• Shaham Y, Erb S, Stewart J. Stress-induced relapse to heroin and cocaine seeking in rats: a review. Brain Res Rev 2000;33(1):13-33
   PubMed Web of Science ®Google Scholar
• Davis WM, Smith SG. Role of conditioned reinforcers in the initiation, maintenance and extinction of drug-seeking behavior. Pavlov J Biol Sci 1976;11(4):222-36
   PubMedGoogle Scholar
• Kreek MJ, Koob GF. Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend 1998;51(1):23-47
   PubMed Web of Science ®Google Scholar
• Sarnyai Z, Shaham Y, Heinrichs SC. The role of corticotropin-releasing factor in drug addiction. Pharmacol Rev 2001;53(2):209-43
   PubMed Web of Science ®Google Scholar
• Ahmed SH, Walker JR, Koob GF. Persistent increase in the motivation to take heroin in rats with a history of drug escalation. Neuropsychopharmacology 2000;22(4):413-21
   PubMed Web of Science ®Google Scholar
• Hjelmstad GO, Xia Y, Margolis EB, Fields HL. Opioid modulation of ventral pallidal afferents to ventral tegmental area neurons. J Neurosci 2013;33(15):6454-9
   PubMed Web of Science ®Google Scholar
• Barbier E, Vendruscolo LF, Schlosburg JE, et al. The NK1 receptor antagonist L822429 reduces heroin reinforcement. Ann Med Vet 2013;38(6):976-84
   Google Scholar
• Largent-Milnes TM, Brookshire SW, Skinner DP, et al. Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects. J Pharmacol Exp Ther 2013;347(1):7-19
   PubMed Web of Science ®Google Scholar
• Largent-Milnes TM, Yamamoto T, Nair P, et al. Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance. Br J Pharmacol 2010;161(5):986-1001
   PubMed Web of Science ®Google Scholar
• Walsh SL, Heilig M, Nuzzo PA, et al. Effects of the NK(1) antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers. Addict Biol 2013;18(2):332-43
   PubMed Web of Science ®Google Scholar
• Xi Z-X, Peng X-Q, Li X, et al. Brain cannabinoid CB2 receptors modulate cocaine’s actions in mice. Nat Neurosci 2011;14(9):1160-6
   PubMed Web of Science ®Google Scholar